17253-11-1

Usage

Uses

Used in Pharmaceutical Industry:
1,4-Benzodioxan-6-ylacetic acid is used as a potential drug candidate for its anti-inflammatory properties, helping to reduce inflammation and associated symptoms in various conditions.
1,4-Benzodioxan-6-ylacetic acid is used as a potential analgesic agent, providing pain relief by targeting specific pain pathways and reducing discomfort.
1,4-Benzodioxan-6-ylacetic acid is used as a potential antipyretic drug, aimed at reducing fever by lowering the body's temperature in response to illness or infection.

InChI:InChI=1/C10H10O4/c11-10(12)6-7-1-2-8-9(5-7)14-4-3-13-8/h1-2,5H,3-4,6H2,(H,11,12)/p-1

Upstream product

• 79-08-3 bromoacetic acid 
• 52287-51-1 6-bromo-1,4-benzodioxane 
• 493-09-4 benzo-1,4-dioxane 
• 102-32-9 3,4-dihydroxyphenylacetate 
• 106-93-4 ethylene dibromide 
• 193885-37-9 2-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-oxoacetic acid 
• 2879-20-1 1,4-benzodioxan-6-yl methyl ketone 
• 177158-18-8 2-(2,3-Dihydro-benzo[1,4]dioxin-6-yl)-1-morpholin-4-yl-ethanethione 

Downstream Products

• 108704-93-4 2-(2,3-dihydro-1,4-benzodioxin-6-yl)acetyl chloride 
• 193885-36-8 2-(2,3-Dihydrobenzo[b][1,4]dioxin-7-yl)propanoic acid 
• 136498-55-0 α-(1,4-benzodioxan-6-yl)-2,4-dihydroxy-5-ethylacetophenone 
• 558641-46-6 1-(5-chloro-2,4-dihydroxyphenyl)-2-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)ethanone 
• 125846-54-0 8-(3-{[2-(3,4-Dimethoxy-phenyl)-ethyl]-methyl-amino}-propyl)-2,3,6,8,9,10-hexahydro-1,4-dioxa-8-aza-cyclohepta[b]naphthalen-7-one 
• 1021174-67-3 4-[2-bromo-5-(propan-2-yloxy)benzyl]-1-[2-(7-chloro-2,3-dihydro-1,4-benzodioxin-6-yl)ethyl]piperidine 
• 1021174-66-2 4-(2-bromo-5-ethoxybenzyl)-1-[2-(7-chloro-2,3-dihydro-1,4-benzodioxin-6-yl)ethyl]-piperidine 
• 1021174-65-1 4-(2-bromo-5-methoxybenzyl)-1-[2-(7-chloro-2,3-dihydro-1,4-benzodioxin-6-yl)ethyl]-piperidine 
• 881656-28-6 2-(2,3-dihydro-1,4-benzodioxin-6-yl)ethyl 4-methylbenzenesulfonate 
• 127264-09-9 1′-(dihydro-3,4-benzodioxinyl)ethan-2′-ol 
• 1375207-29-6 (E)-2-(3,4-(ethylenedioxy)phenyl)-3-(3,4-dimethoxyphenyl)acrylic acid 
• 558641-79-5 6-chloro-3-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-7-hydroxy-2-methyl-4H-chromen-4-one 

Relevant academic research and scientific papers

Ether modifications to 1-[2-(3,4-dimethoxyphenyl)ethyl]-4-(3-phenylpropyl)piperazine (SA4503): Effects on binding affinity and selectivity for sigma receptors and monoamine transporters

Two series of novel ether analogs of the sigma (σ) receptor ligand 1-[2-(3,4-dimethoxyphenyl)ethyl]-4-(3-phenylpropyl)piperazine (SA4503) have been prepared. In one series, the alkyl portion of the 4-methoxy group was replaced with allyl, propyl, bromoethyl, benzyl, phenethyl, and phenylpropyl moieties. In the second series, the 3,4-dimethoxy was replaced with cyclic methylenedioxy, ethylenedioxy and propylenedioxy groups. These ligands, along with 4-O-des-methyl SA4503, were evaluated for σ1 and σ2 receptor affinity, and compared to SA4503 and several known ether analogs. SA4503 and a subset of ether analogs were also evaluated for dopamine transporter (DAT) and serotonin transporter (SERT) affinity. The highest σ1 receptor affinities, Ki values of 1.75-4.63 nM, were observed for 4-O-des-methyl SA4503, SA4503 and the methylenedioxy analog. As steric bulk increased, σ1 receptor affinity decreased, but only to a point. Allyl, propyl and bromoethyl substitutions gave σ1 receptor Ki values in the 20-30 nM range, while bulkier analogs having phenylalkyl, and Z- and E-iodoallyl, ether substitutions showed higher σ1 affinities, with Ki values in the 13-21 nM range. Most ligands studied exhibited comparable σ1 and σ2 affinities, resulting in little to no subtype selectivity. SA4503, the fluoroethyl analog and the methylenedioxy congener showed modest six- to fourteen-fold selectivity for σ1 sites. DAT and SERT interactions proved much more sensitive than σ receptor interactions to these structural modifications. For example, the benzyl congener (σ1 Ki = 20.8 nM; σ2 Ki = 16.4 nM) showed over 100-fold higher DAT affinity (Ki = 121 nM) and 6-fold higher SERT affinity (Ki = 128 nM) than the parent SA4503 (DAT Ki = 12650 nM; SERT Ki = 760 nM). Thus, ether modifications to the SA4503 scaffold can provide polyfunctional ligands having a broader spectrum of possible pharmacological actions.

PURINE DERIVATIVES USEFUL AS HSP90 INHIBITORS

The present application provides substituted purine derivatives and related compounds of the formulas shown. These com ounds are useful as inhibitors of HSP90, and hence in the treatment of related diseases. (Formulae) Z1-Z3, Xa-Xc, X2, X4, Y and R are as defined in the specification.

SUBSTITUTED AROMATIC CARBOXAMIDE AND UREA DERIVATIVES AS VANILLOID RECEPTOR LIGANDS

The invention relates to substituted aromatic carboxamide and urea derivatives, to processes for the preparation thereof, to pharmaceutical compositions containing these compounds and also to the use of these compounds for preparing pharmaceutical compositions (formula (I)).

Synthesis and biological activity of new anti-inflammatory compounds containing the 1,4-benzodioxine and/or pyrrole system

A series of substituted derivatives containing the 1,4-benzodioxine or pyrrole nucleus are described. All the newly synthesized compounds were examined for their in vitro and in vivo anti-inflammatory activity. Several derivatives, including (S)-2, 14 and 17, showed more anti-inflammatory activity in vivo in these assays (rat paw oedema induced by carrageenan) than the known classical anti-inflammatory agent ibuprofen, whereas other compounds like 1 were equipotent to ibuprofen. Compound 17 was the most outstanding derivative because of its remarkable in vivo anti-inflammatory activity. In this paper, we examine and discuss the structure-activity relationships and anti-inflammatory activities of these compounds.

Cyanoamidine P2X7 antagonists for the treatment of pain

Novel cyanoamidines compounds of formula (I) and (II) and their derivatives wherein R1-R12 are as defined in the specification act as antagonists of the P2X7 receptor. These compounds are particularly useful in the treatment of pain, inflammation and neurodegeneration states.

Synthesis and anti-inflammatory activity of rac-2-(2,3-dihydro-1,4-benzodioxin)propionic acid and its R and S enantiomers

Racemic (R,S)-2-(2,3-dihydro-1,4-benzodioxin-6-yl)propionic acid (3) has been prepared from 2,3-dihydro-1,4-benzodioxin. R-(-)-Pantolactone has been used as auxiliary for the synthesis of R-3 and S-3. The anti-inflammatory properties of the new carboxylic acids are described and compared with other anti-inflammatory agents. The highest activity is exhibited by compound S-3.

Synthesis and antiinflammatory activity of 2,3-dihydro-1,4-benzodioxin methyl carboxylic acids

Synthesis and antiinflammatory properties of new carboxylic acids containing the 2,3-dihydro-1,4-benzodioxin subunit are described. The 2-(2,3-dihydro-1,4-benzodioxin-6-yl)acetic acid was of comparable potency to Ibuprofen, in carrageenan induced rat paw edema assay.

Method of inhibiting sweetness

The sweetness of an ingestible product containing a sweetening sugar or sugar alcohol in large quantities can be reduced by incorporating therein a sweetness-reducing amount of at least one compound of the general formula: STR1 in which m represents 0 or 1, and when m represents 0, n represents 1, 2 or 3, and p represents 1, 2, 3 or 4, and when m represents 1, n represents 1 or 2 and p represents 0, 1, 2, 3 or 4; the substituents R, which may be the same or different, each represent a lower alkoxy group, e.g. with 1 to 5 carbon atoms, phenoxy group or a lower alkyl or trifluoromethyl group; and/or two substituents R together represent an aliphatic chain linked to the phenyl ring at two positions, either directly or via an oxa-group, e.g. an alkylenedioxy, alkenylenedioxy, alkylenoxy or alkenylenoxy group; and/or one substituent R represents a hydroxy group while at least one other substituent R represents an alkoxy group; and X+ represents a physiologically acceptable cation.